[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

GSK's Vaccine Momentum Meets the HIV Patent Cliff This Week—Can Specialty Medicine Bridge the Gap?

GSK plc reports first-quarter 2026 earnings on April 29, 2026 before market open, with Wall Street expecting $1.17 per share on revenue of approximately $10.23 billion. The pharmaceutical giant has beaten revenue estimates in three consecutive quarters, but the central question is whether its vaccine portfolio and specialty medicines can sustain momentum amid pricing pressures and competitive dynamics. With the stock trading below most short-term moving averages and an options market pricing a 3.78% expected move, investors will scrutinize forward guidance and pipeline updates for signals on the sustainability of GSK's recent earnings strength.

GSK plc is a London-headquartered multinational pharmaceutical company focused on vaccines, specialty...

Fundamentals

See More
  • Market Capitalization, $K 110,530,416
  • Shares Outstanding, K 2,029,198
  • Annual Sales, $ 43,078 M
  • Annual Income, $ 7,538 M
  • EBIT $ 10,460 M
  • EBITDA $ 13,511 M
  • 60-Month Beta 0.46
  • Price/Sales 2.55
  • Price/Cash Flow 9.03
  • Price/Book 5.25

Options Overview Details

View History
  • Implied Volatility 31.14% (-2.03%)
  • Historical Volatility 29.30%
  • IV Percentile 76%
  • IV Rank 32.69%
  • IV High 61.51% on 10/23/25
  • IV Low 16.39% on 12/08/25
  • Expected Move (DTE 1) 1.11 (2.15%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 8,703
  • Volume Avg (30-Day) 4,102
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 106,330
  • Open Int (30-Day) 68,091
  • Expected Range 50.30 to 52.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.16
  • Number of Estimates 4
  • High Estimate $1.19
  • Low Estimate $1.13
  • Prior Year $1.13
  • Growth Rate Est. (year over year) +2.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.99 +2.83%
on 04/29/26
59.57 -13.71%
on 04/14/26
-2.44 (-4.53%)
since 03/27/26
3-Month
49.99 +2.83%
on 04/29/26
61.69 -16.69%
on 02/18/26
+0.74 (+1.46%)
since 01/29/26
52-Week
35.45 +44.99%
on 07/17/25
61.69 -16.69%
on 02/18/26
+12.43 (+31.90%)
since 04/29/25

Most Recent Stories

More News
GSK's Vaccine Momentum Meets the HIV Patent Cliff This Week—Can Specialty Medicine Bridge the Gap?

Barchart Research What to Expect from GSK Earnings GSK Generated April 28, 2026 Current Price $54.47 EPS Estimate $$1.17 Consensus Rating Hold Average Move 4.32% GSK's Vaccine Momentum Meets the HIV Patent...

GSK : 51.40 (-5.64%)
3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

WEN : 6.76 (-0.73%)
INVA : 23.05 (-2.70%)
GSK : 51.40 (-5.64%)
NBR : 104.18 (+11.28%)
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas

BORAY : 2.9000 (-0.68%)
GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 51.40 (-5.64%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 51.40 (-5.64%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Grant funding awarded to support lupus-focused community programs across the United States

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 227.35 (-0.19%)
LLY : 851.21 (-2.61%)
ABBV : 203.89 (+3.14%)
GSK : 51.40 (-5.64%)
CSLLY : 22.2400 (-3.47%)
PFE : 26.26 (-0.83%)
SNY : 46.03 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 54.50
2nd Resistance Point 53.32
1st Resistance Point 52.36
Last Price 51.40
1st Support Level 50.21
2nd Support Level 49.03
3rd Support Level 48.07

See More

52-Week High 61.69
Fibonacci 61.8% 51.67
Last Price 51.40
Fibonacci 50% 48.57
Fibonacci 38.2% 45.48
52-Week Low 35.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.